Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
Schran
Horst F
HF
Hager
Douglas F
DF
D018931:Antineoplastic Agents, Hormonal / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001682:Biological Availability; D002276:Carcinoid Tumor / Q000188:drug therapy* / Q000378:metabolism; D016903:Drug Monitoring; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000378:metabolism; D015282:Octreotide / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D012107:Research Design; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide